Despite several high-profile setbacks, Eli Lilly has agreed to in-license AC Immune’s tau aggregation inhibitors for the treatment of Alzheimer’s disease and other neurodegenerative diseases for a total potential deal value of CHF1840 M (US$1858.32). The agreement grants Lilly worldwide rights to a series of small molecules identified using AC Immune’s Morphomer™ platform including its lead asset, ACI-3024, which showed promising results in preclinical studies.